Trial reportBMC immunology2025
Zinc as a therapeutic adjunct: enhancing t-cell reconstitution in hematopoietic stem cell transplant recipients-a double-blind clinical study.
Trial report in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective immune reconstitution (IR) following hematopoietic stem cell transplantation (HSCT) is vital for increasing long-term patient survival and reducing the risk of posttransplant infections. A key indicator of successful immune recovery is the generation of recent thymic-enriched T cells (RTEs), which directly reflects thymic activity. Zinc (Zn), an essential trace element, has been shown to play a pivotal role in supporting immune function and thymic output. This study assessed how Zn supplementation influences RTE levels and overall immune recovery in patients undergoing HSCT.
methodsIn this double-blind, randomized, placebo-controlled clinical trial, 38 patients who underwent autologous HSCT were randomly assigned to receive either Zn supplementation (n = 19) or placebo (n = 19). The intervention group was administered three 30 mg Zn gluconate tablets daily during the first 30 days post-transplant, followed by one tablet daily from day 31 to day 90. T-cell subsets, including RTEs, were measured via flow cytometry at baseline, day 30, and day 90. Absolute lymphocyte counts (ALCs) were also monitored. Nutritional intake and serum Zn and copper levels were assessed to control for dietary confounders.
resultsOn day 90 posttransplant, patients receiving Zn supplementation presented a significantly greater ALC than did those in the placebo group (p = 0.009). Furthermore, the Zn group presented a substantial increase in the percentage of RTEs at both day 30 (p = 0.008) and day 90 (p = 0.025), whereas the placebo group did not demonstrate changes. These findings suggest that Zn supplementation positively influences thymic output and contributes to early T-cell reconstitution.
conclusionZn supplementation facilitates immune recovery following autologous HSCT by increasing ALC and RTE generation. These results highlight the potential utility of Zn as an adjunctive therapy to promote thymic regeneration and immune competence in transplant recipients.
trial registrationIRCT20191211045701N1/Date: 2020–06-12. This registration confirms adherence to ethical standards and facilitates verification of study details from 2020–06–12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.